Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies

被引:33
作者
Petrelli, Fausto [1 ]
Luciani, Andrea [1 ]
Borgonovo, Karen [1 ]
Ghilardi, Mara [1 ]
Parati, Maria Chiara [1 ]
Petro, Daniela [1 ]
Lonati, Veronica [1 ]
Pesenti, Angelo [2 ]
Cabiddu, Mary [1 ]
机构
[1] ASST Bergamo Ovest, Oncol Unit, Med Sci Dept, Piazzale Osped 1, I-24047 Bergamo, Italy
[2] ASST Bergamo Ovest, Lab Med Unit, Clin Diagnost Dept, Bergamo, Italy
关键词
booster; COVID-19; third dose; vaccination;
D O I
10.1002/jmv.27644
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We analyzed published studies on the efficacy and safety of the third dose of the COVID-19 vaccine in various general population settings. We conducted systematic searches of PubMed and EMBASE for series published in the English language through November 15, 2021, using the search terms "third" or "booster" or "three" and "dose" and "COVID-19" or "SARS-CoV-2." All articles were selected according to the MOOSE guidelines. The seroconversion risk after third doses was descriptively expressed as a pooled rate ratio ([seroconversion rate after the third dose]/[seroconversion rate after the second dose]). The search returned 30 studies that included a total of 2 734 437 vaccinated subjects. In more than 2 700 000 Israeli patients extracted from the general population, the reduction in the risk of infection ranged from 88% to 92%. Conversion rates for IgG anti-spike ranged from 95% to 100%. In cancer or immunocompromised patients, mean IgG seroconversion was 39.4% before and 66.6% after third doses. A third dose seems necessary to protect against all COVID-19 infection, severe disease, and death risk.
引用
收藏
页码:2837 / 2844
页数:8
相关论文
共 7 条
[1]   Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].
Bar-On, Yinon M. ;
Goldberg, Yair ;
Mandel, Micha ;
Bodenheimer, Omri ;
Freedman, Laurence ;
Kalkstein, Nir ;
Mizrahi, Barak ;
Alroy-Preis, Sharon ;
Ash, Nachman ;
Milo, Ron ;
Huppert, Amit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400
[2]   Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors-A nationwide survey [J].
Ben David, Shirley Shapiro ;
Shamir-Stein, Na'ama ;
Gez, Sharon Baruch ;
Lerner, Uri ;
Rahamim-Cohen, Daniella ;
Zohar, Anat Ekka .
CLINICAL IMMUNOLOGY, 2021, 232
[3]   Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial [J].
Bergman, Peter ;
Blennow, Ola ;
Hansson, Lotta ;
Mielke, Stephan ;
Nowak, Piotr ;
Chen, Puran ;
Soderdahl, Gunnar ;
Osterborg, Anders ;
Smith, C. I. Edvard ;
Wullimann, David ;
Vesterbacka, Jan ;
Lindgren, Gustaf ;
Blixt, Lisa ;
Friman, Gustav ;
Wahren-Borgstrom, Emilie ;
Nordlander, Anna ;
Gomez, Angelica Cuapio ;
Akber, Mira ;
Valentini, Davide ;
Norlin, Anna-Carin ;
Thalme, Anders ;
Bogdanovic, Gordana ;
Muschiol, Sandra ;
Nilsson, Peter ;
Hober, Sophia ;
Lore, Karin ;
Chen, Margaret Sallberg ;
Buggert, Marcus ;
Ljunggren, Hans-Gustaf ;
Ljungman, Per ;
Aleman, Soo .
EBIOMEDICINE, 2021, 74
[4]   SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 [J].
Cohn, Barbara A. ;
Cirillo, Piera M. ;
Murphy, Caitlin C. ;
Krigbaum, Nickilou Y. ;
Wallace, Arthur W. .
SCIENCE, 2022, 375 (6578) :331-+
[5]   Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis [J].
Cromer, Deborah ;
Steain, Megan ;
Reynaldi, Arnold ;
Schlub, Timothy E. ;
Wheatley, Adam K. ;
Juno, Jennifer A. ;
Kent, Stephen J. ;
Triccas, James A. ;
Khoury, David S. ;
Davenport, Miles P. .
LANCET MICROBE, 2022, 3 (01) :E52-E61
[6]   Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021 [J].
Hause, Anne M. ;
Baggs, James ;
Gee, Julianne ;
Marquez, Paige ;
Myers, Tanya R. ;
Shimabukuro, Tom T. ;
Shay, David K. .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (39) :1379-1384
[7]   COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations [J].
Yan, Zhipeng ;
Yang, Ming ;
Lai, Ching-Lung .
VACCINES, 2021, 9 (10)